AR034700A1 - Derivados de pirimidina,procesos para prepararlos, composiciones farmaceuticas que los comprenden, y el uso de dichos compuestos para la elaboracion de medicamentos - Google Patents
Derivados de pirimidina,procesos para prepararlos, composiciones farmaceuticas que los comprenden, y el uso de dichos compuestos para la elaboracion de medicamentosInfo
- Publication number
- AR034700A1 AR034700A1 ARP010105229A ARP010105229A AR034700A1 AR 034700 A1 AR034700 A1 AR 034700A1 AR P010105229 A ARP010105229 A AR P010105229A AR P010105229 A ARP010105229 A AR P010105229A AR 034700 A1 AR034700 A1 AR 034700A1
- Authority
- AR
- Argentina
- Prior art keywords
- compounds
- alkyl
- processes
- pharmaceutical compositions
- medicines
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 239000003814 drug Substances 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 5
- 125000004183 alkoxy alkyl group Chemical group 0.000 abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- -1 hydroalkoxyalkyl Chemical group 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 2
- 208000030814 Eating disease Diseases 0.000 abstract 1
- 208000019454 Feeding and Eating disease Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 125000005083 alkoxyalkoxy group Chemical group 0.000 abstract 1
- 125000004103 aminoalkyl group Chemical group 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 206010003246 arthritis Diseases 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 235000014632 disordered eating Nutrition 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 125000001188 haloalkyl group Chemical group 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 125000005113 hydroxyalkoxy group Chemical group 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- BPGXUIVWLQTVLZ-OFGSCBOVSA-N neuropeptide y(npy) Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 BPGXUIVWLQTVLZ-OFGSCBOVSA-N 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 abstract 1
- 150000003230 pyrimidines Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Diabetes (AREA)
- Public Health (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Physical Education & Sports Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Nutrition Science (AREA)
- Child & Adolescent Psychology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Derivados de pirimidina que tienen la fórmula (1) en donde R1 y R2 son cada uno independientemente alquilo, cicloalquilo o aralquilo o uno de R1 y R2 es hidrógeno y el otro es alquilo, aminoalquilo o ciclopropilo o R1 y R2 junto con el átomo de N al que están unidos forman un anillo heterocíclico de 4 a 10 miembros opcionalmente sustituido con de uno a tres sustituyentes independientemente seleccionados de alquilo, hidroxi, alcoxi, alcoxialquilo, hidroxialquilo o CONR5R6; R3 es alquilo, cicloalquilo, alcoxialquilo, hidroxialquilo, haloalquilo, alcoxi, alcoxialcoxi, hidro-alcoxialquilo, hidroxialcoxi, aralquilo o amino; R4 es arilo o heteroarilo, en donde R4 no es nitrofurilo o nitrotienilo; R5 y R6 son cada uno independientemente hidrógeno o alquilo; A1 es CH o N; A2 es CH o N; en donde uno de A1 y A2 es N y el otro es CH; y ésteres y sales utilizables farmacéuticamente de los mismos. Dichos compuestos son útiles como ligandos del receptor del neuropéptido Y (NPY), particularmente como antagonistas del neuropéptido Y (NPY). En consecuencia, estos compuestos son útiles en la profilaxis y tratamiento de la artritis, diabetes, trastornos alimentarios y obesidad. También se dan a conocer procesos para la preparación de dichos compuestos, composiciones farmacéuticas que los comprenden, y el uso de dichos compuestos para la elaboración de medicamentos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP00124610 | 2000-11-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR034700A1 true AR034700A1 (es) | 2004-03-17 |
Family
ID=8170342
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP010105229A AR034700A1 (es) | 2000-11-10 | 2001-11-08 | Derivados de pirimidina,procesos para prepararlos, composiciones farmaceuticas que los comprenden, y el uso de dichos compuestos para la elaboracion de medicamentos |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US6657060B2 (es) |
| EP (1) | EP1335906B1 (es) |
| JP (1) | JP2004524279A (es) |
| KR (1) | KR100611853B1 (es) |
| CN (1) | CN1473156A (es) |
| AR (1) | AR034700A1 (es) |
| AT (1) | ATE340784T1 (es) |
| AU (2) | AU2002227905B2 (es) |
| BR (1) | BR0115045A (es) |
| CA (1) | CA2427350A1 (es) |
| DE (1) | DE60123458T2 (es) |
| DK (1) | DK1335906T3 (es) |
| ES (1) | ES2271100T3 (es) |
| MX (1) | MXPA03004136A (es) |
| PA (1) | PA8531701A1 (es) |
| PE (1) | PE20020603A1 (es) |
| PT (1) | PT1335906E (es) |
| UY (1) | UY27018A1 (es) |
| WO (1) | WO2002038551A1 (es) |
| ZA (1) | ZA200302970B (es) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ534757A (en) | 2002-03-12 | 2006-07-28 | Merck & Co Inc | Substituted amides |
| CN1642422A (zh) * | 2002-03-15 | 2005-07-20 | 西巴特殊化学品控股有限公司 | 4－氨基嘧啶及其在表面抗菌处理中的应用 |
| GB0428328D0 (en) | 2004-12-24 | 2005-02-02 | Astrazeneca Uk Ltd | Chemical process |
| US7768604B2 (en) * | 2005-09-20 | 2010-08-03 | Au Optronics Corporation | Transflective liquid crystal display with partially shifted reflectivity curve |
| GB0616747D0 (en) * | 2006-08-24 | 2006-10-04 | Astrazeneca Ab | Novel compounds |
| WO2007080382A1 (en) * | 2006-01-11 | 2007-07-19 | Astrazeneca Ab | Morpholino pyrimidine derivatives and their use in therapy |
| CA2660758A1 (en) | 2006-08-24 | 2008-02-27 | Astrazeneca Ab | Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders |
| JP2010501537A (ja) * | 2006-08-24 | 2010-01-21 | アストラゼネカ アクチボラグ | 増殖性障害の治療に有用なモルホリノピリミジン誘導体 |
| WO2009007749A2 (en) * | 2007-07-09 | 2009-01-15 | Astrazeneca Ab | Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases |
| BRPI0814818A2 (pt) * | 2007-07-09 | 2019-09-10 | Astrazeneca Ab | composto, uso de um composto, métodos para produzir um efeito anti-proliferativo e um efeito inibitório de mtor quinase em uma animal de sangue quente, método para tratar doenças, e, composição farmacêutica |
| CA2692720A1 (en) | 2007-07-09 | 2009-01-15 | Astrazeneca Ab | Morpholino pyrimidine derivatives used in diseases linked to mtor kinase and/or pi3k |
| CA2692725A1 (en) * | 2007-07-09 | 2009-01-15 | Astrazeneca Ab | Compound - 946 |
| US20110166135A1 (en) * | 2008-09-10 | 2011-07-07 | Hiroshi Morimoto | Aromatic nitrogen-containing 6-membered ring compounds and their use |
| TW201028410A (en) * | 2008-12-22 | 2010-08-01 | Astrazeneca Ab | Chemical compounds 610 |
| JP2011201873A (ja) * | 2010-03-03 | 2011-10-13 | Mitsubishi Tanabe Pharma Corp | 三置換ピリミジン化合物及びそのｐｄｅ１０阻害薬としての使用 |
| AU2011224697A1 (en) * | 2010-03-11 | 2012-10-04 | Targacept, Inc. | Arylvinylazacycloalkane compounds for constipation |
| SA111320519B1 (ar) | 2010-06-11 | 2014-07-02 | Astrazeneca Ab | مركبات بيريميدينيل للاستخدام كمثبطات atr |
| WO2015039292A1 (zh) * | 2013-09-18 | 2015-03-26 | 华安医学股份有限公司 | 一种活化ampk的化合物及其用途 |
| CN112375042A (zh) * | 2020-10-27 | 2021-02-19 | 安徽医科大学 | 三甲氧基苯乙烯基六元环类和吡唑并嘧啶类化合物、制剂及其制备与应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH024345A (ja) * | 1988-06-15 | 1990-01-09 | Matsushita Electric Ind Co Ltd | 超音波変換装置 |
| JPH0720467B2 (ja) * | 1988-06-15 | 1995-03-08 | 松下電器産業株式会社 | 超音波診断装置 |
| WO1994007867A1 (en) | 1992-09-28 | 1994-04-14 | Pfizer Inc. | Substituted pyrimidines for control of diabetic complications |
| WO1997034873A1 (en) | 1996-03-21 | 1997-09-25 | Banyu Pharmaceutical Co., Ltd. | Aminopyridine derivatives |
| WO1998040356A1 (en) * | 1997-03-12 | 1998-09-17 | Banyu Pharmaceutical Co., Ltd. | Drugs containing aminopyridine derivatives as the active ingredient |
-
2001
- 2001-11-06 AU AU2002227905A patent/AU2002227905B2/en not_active Ceased
- 2001-11-06 MX MXPA03004136A patent/MXPA03004136A/es active IP Right Grant
- 2001-11-06 PT PT01989438T patent/PT1335906E/pt unknown
- 2001-11-06 BR BR0115045-6A patent/BR0115045A/pt not_active IP Right Cessation
- 2001-11-06 DK DK01989438T patent/DK1335906T3/da active
- 2001-11-06 CN CNA018186343A patent/CN1473156A/zh active Pending
- 2001-11-06 WO PCT/EP2001/012818 patent/WO2002038551A1/en not_active Ceased
- 2001-11-06 JP JP2002541086A patent/JP2004524279A/ja active Pending
- 2001-11-06 DE DE60123458T patent/DE60123458T2/de not_active Expired - Fee Related
- 2001-11-06 KR KR1020037006306A patent/KR100611853B1/ko not_active Expired - Fee Related
- 2001-11-06 AT AT01989438T patent/ATE340784T1/de not_active IP Right Cessation
- 2001-11-06 CA CA002427350A patent/CA2427350A1/en not_active Abandoned
- 2001-11-06 ES ES01989438T patent/ES2271100T3/es not_active Expired - Lifetime
- 2001-11-06 EP EP01989438A patent/EP1335906B1/en not_active Expired - Lifetime
- 2001-11-06 AU AU2790502A patent/AU2790502A/xx active Pending
- 2001-11-07 PA PA20018531701A patent/PA8531701A1/es unknown
- 2001-11-08 US US10/008,166 patent/US6657060B2/en not_active Expired - Fee Related
- 2001-11-08 PE PE2001001110A patent/PE20020603A1/es not_active Application Discontinuation
- 2001-11-08 AR ARP010105229A patent/AR034700A1/es unknown
- 2001-11-09 UY UY27018A patent/UY27018A1/es not_active Application Discontinuation
-
2003
- 2003-04-15 ZA ZA200302970A patent/ZA200302970B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1335906A1 (en) | 2003-08-20 |
| ATE340784T1 (de) | 2006-10-15 |
| ZA200302970B (en) | 2004-07-15 |
| DE60123458T2 (de) | 2007-08-02 |
| PT1335906E (pt) | 2007-01-31 |
| UY27018A1 (es) | 2002-06-20 |
| ES2271100T3 (es) | 2007-04-16 |
| AU2002227905B2 (en) | 2006-10-05 |
| DK1335906T3 (da) | 2007-02-05 |
| KR100611853B1 (ko) | 2006-08-11 |
| MXPA03004136A (es) | 2003-08-19 |
| WO2002038551A1 (en) | 2002-05-16 |
| AU2790502A (en) | 2002-05-21 |
| JP2004524279A (ja) | 2004-08-12 |
| PE20020603A1 (es) | 2002-07-20 |
| US6657060B2 (en) | 2003-12-02 |
| CN1473156A (zh) | 2004-02-04 |
| EP1335906B1 (en) | 2006-09-27 |
| KR20040004432A (ko) | 2004-01-13 |
| US20020086858A1 (en) | 2002-07-04 |
| PA8531701A1 (es) | 2003-06-30 |
| BR0115045A (pt) | 2004-02-03 |
| DE60123458D1 (de) | 2006-11-09 |
| CA2427350A1 (en) | 2002-05-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR034700A1 (es) | Derivados de pirimidina,procesos para prepararlos, composiciones farmaceuticas que los comprenden, y el uso de dichos compuestos para la elaboracion de medicamentos | |
| BRPI0418082B8 (pt) | derivados de tiazol úteis como antagonistas de receptor de adenosina a2a | |
| AR040626A1 (es) | Derivados de quinolina utiles como ligandos del receptor del neuropeptido y (npy) | |
| AR063602A1 (es) | Derivados de espiroindolinona, formulaciones farmaceuticas que los contienen y su uso en la obtencion de un medicamento para el tratamiento de trastornos oncologicos. | |
| AR058769A1 (es) | Inhibidores de peptidil-deformilasa(pdf),utiles para el tratamiento de la tuberculosis y composiciones farmaceuticas que los contienen. | |
| AR030596A1 (es) | Derivados de quinolina y quinazolina, un procedimiento para su preparacion, composicion farmaceutica que los comprende, uso de los mismos para la elaboracion de medicamentos | |
| DK1412354T3 (da) | Derivater af triazolylimidazopyridin og af triazolylpurinerne, der er egnede som ligander for adenosin A2a?-receptoren og deres anvendelse som medikamenter | |
| BR0306208A (pt) | Compostos de dibenzilamina e seu uso farmacêutico | |
| ECSP045367A (es) | "derivados de bencimidazol utiles como antagonistas de histamina h3" | |
| AR038249A1 (es) | Compuestos derivados de quinolina, procedimientos para su preparacion, composiciones farmaceuticas que los comprenden, y uso de dichos compuestos derivados en la preparacion de un medicamento | |
| AR035979A1 (es) | Derivados de quinolina, procedimientos para su preparacion, composiciones farmaceuticas que los comprenden, y usos de dichos compuestos para la preparacion de medicament0s | |
| AR083339A1 (es) | Compuestos de quinazolina como bloqueadores de los canales de sodio | |
| AR066460A2 (es) | Compuestos derivados de fenil-piperazina, fenil-piperidina y fenil-tetrahidropiridina como inhibidores de la reabsorcion de la serotonina, una composicion farmaceutica y utilizacion de los mismos para la preparacion de medicamentos | |
| AR030507A1 (es) | Compuesto de pirazolopiridina y los usos farmaceuticos del mismo | |
| NO20080456L (no) | Nye 2,4-dianilinopyrimidinderivater, fremstilling derav og deres anvendelse som medikamenter, farmasoytiske sammensetninger og, spesielt, som IKK inhibitorer | |
| AR031597A1 (es) | Compuestos piperidinos,un proceso para su preparacion, composiciones farmaceuticas,y el uso de dichos compuestos para la fabricacion de un medicamento para uso como inhibidores ccr-3 | |
| AR067412A1 (es) | Moduladores de propiedades farmaceuticas de productos terapeuticos | |
| BRPI0607600A2 (pt) | derivados de 4-oxoquinazolin-3-il-benzamida para o tratamento de doenças relacionadas com citocina | |
| AR019167A1 (es) | Derivados heteroaromaticos de piperazinas di-n-sustituidas y piperidinas 1,4-disustituidas, composiciones farmaceuticas y el uso de los mismos para lapreparacion de medicamentos | |
| BRPI0519288A2 (pt) | compostos heterocÍclicos como antagonistas de ccr2b | |
| AR124973A1 (es) | Nuevos derivados de pirimidina-2-il sulfonamida | |
| AR050208A1 (es) | Compuesto de heteroaril sulfonamida sustituida, procedimiento para la preparacion del mismo, composicion farmaceutica que lo comprende y su uso para preparar un medicamento | |
| AR033996A1 (es) | Una 7-oxo-piridopirimidina, su uso, un proceso para prepararla, una composicion farmaceutica que la comprende, un proceso para producir una pirimidina, un proceso para producir una piridopirimidina, y compuestos preparados mediante dichos procesos | |
| AR038704A1 (es) | Derivados de tiazol como antagonistas del receptor nyp | |
| AR068111A1 (es) | Compuesto de pirazina y piperidina piperazinil sustituida, composicion farmaceutica que lo comprende y su uso para preparar un medicamento |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |